Chiron Real Estate Inc

Análisis de la acción Chiron Real Estate Inc (XRN)

$30.000

-0.159 (-0.53%)Al cierre

Loading chart…
Máximo
30.270
Apertura
30.000
Precio medio ponderado por volumen
29.96
Volumen
311.32K
Capitalización
—
Mínimo
29.610
Importe
9.33M
EV/EBITDA, TTM
10.93

Chiron Real Estate Inc. is an internally managed real estate investment trust (REIT) that owns healthcare facilities leased to physician groups and regional and national healthcare systems and seniors housing communities. The Company's seniors' housing includes independent living communities, assisted living communities, memory care communities, and active adult communities. The Company holds its facilities and conducts its operations through its limited partnership subsidiary, Chiron Real Estate LP (the Operating Partnership). The Company owns 91.3% of the outstanding common operating partnership units (OP Units), with the remaining 8.7% owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services in exchange for OP Units. Its investment portfolio consists of healthcare facilities, primarily outpatient medical facilities, seniors housing operating portfolio (SHOP) assets, joint ventures and other investments.

www.chironre.com

Análisis de IA of Chiron Real Estate Inc (XRN)

Mantener

Chiron Real Estate Inc (XRN) is currently trading at $30.34, which is significantly below the average analyst price target of $43, indicating potential upside. However, the stock has a very low RSI of 6.158, suggesting it is oversold, but this could also indicate underlying issues. The company reported a remarkable net income of $63.29 million in Q2 2026, showing strong recovery, but it also has a forward P/E ratio of 714.29, indicating potential overvaluation concerns. Given these mixed signals, it is prudent to hold rather than buy at this time.

Métricas de valoración

El PER previsto actual de Chiron Real Estate Inc (XRN) es 714.29, frente a su media de 5 años de 297.71.

PER previsto

Sobrevalorado
Media 5A P/E
297.71
P/E actual
714.29
Sobrevalorada
521.03
Infravalorada
74.38

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
12.42
EV/EBITDA actual
10.93
Sobrevalorada
14.32
Infravalorada
10.51

Precio/ventas previsto

Valor razonable
Media 5A P/S
3.68
P/S actual
2.71
Sobrevalorada
4.75
Infravalorada
2.60

Ballenas con XRN en cartera

H

Heartland Advisors, Inc.

+ Con en carteraXRN

+1.90%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-07 (ET)

16:30:00

Chiron Real Estate Appoints Charles P. Fitzgerald as Chairman of the Board

2026-08-05 (ET)

17:30:00

Chiron CEO Highlights Progress in Capital Allocation and Investments

2026-08-03 (ET)

17:00:00

Chiron Appoints Matthew Whitlock as Chief Investment Officer

2026-07-17 (ET)

17:00:00

Chiron Real Estate Appoints New Executives

2026-07-14 (ET)

16:30:00

Chiron Real Estate Appoints New Executive Team

Noticias

Preguntas frecuentes sobre XRN, respondidas por Alphio AI

Chiron Real Estate Inc. is an internally managed real estate investment trust (REIT) that owns healthcare facilities leased to physician groups and regional and national healthcare systems and seniors housing communities. The Company's seniors' housing includes independent living communities, assisted living communities, memory care communities, and active adult communities. The Company holds its facilities and conducts its operations through its limited partnership subsidiary, Chiron Real Estate LP (the Operating Partnership). The Company owns 91.3% of the outstanding common operating partnership units (OP Units), with the remaining 8.7% owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services in exchange for OP Units. Its investment portfolio consists of healthcare facilities, primarily outpatient medical facilities, seniors housing operating portfolio (SHOP) assets, joint ventures and other investments. It operates in the Real Estate sector.

Chiron Real Estate Inc (XRN) is currently trading at $30.34, which is significantly below the average analyst price target of $43, indicating potential upside. However, the stock has a very low RSI of 6.158, suggesting it is oversold, but this could also indicate underlying issues. The company reported a remarkable net income of $63.29 million in Q2 2026, showing strong recovery, but it also has a forward P/E ratio of 714.29, indicating potential overvaluation concerns. Given these mixed signals, it is prudent to hold rather than buy at this time.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar